Subtopic Deep Dive
Progressive Myoclonus Epilepsies
Research Guide
What is Progressive Myoclonus Epilepsies?
Progressive Myoclonus Epilepsies (PME) are a group of rare genetic neurodegenerative disorders characterized by worsening myoclonic jerks, generalized seizures, and progressive ataxia.
PME encompasses etiologies like Unverricht-Lundborg disease and EPM1 from cystatin B deficiency, often following autosomal recessive inheritance (Norio and Koskiniemi, 1979; 135 citations). Classification systems distinguish PME from related disorders (Andermann and Andermann, 1990; 156 citations). Over 100 Finnish cases highlight nosological patterns (Norio and Koskiniemi, 1979).
Why It Matters
PME classification refines differential diagnosis, separating glycogen-related myoclonus from pure PME for targeted therapies (Andermann and Andermann, 1990). Genetic insights into cystatin B deficiency reveal oxidative stress mechanisms sensitizing neurons (Lehtinen et al., 2009). GLUT1 deficiency identification enables treatable myoclonic-astatic epilepsy cases (Mullen et al., 2011). Unstable repeat expansions in MARCH6 link to familial adult myoclonic epilepsy, guiding genetic testing (Florian et al., 2019).
Key Research Challenges
Genetic Heterogeneity
PME spans diverse mutations like cystatin B in EPM1 and MARCH6 expansions (Lehtinen et al., 2009; Florian et al., 2019). Sibship analysis in 107 Finnish patients shows recessive patterns but variable expressivity (Norio and Koskiniemi, 1979). Nosological classification remains debated (Andermann and Andermann, 1990).
Neurodegenerative Mechanisms
Cystatin B deficiency heightens neuronal oxidative stress in EPM1 (Lehtinen et al., 2009). Cerebellar atrophy correlates with myoclonus progression, lacking clear biomarkers. Finnish cohort data indicate ataxia and cognitive decline trajectories (Norio and Koskiniemi, 1979).
Treatment Efficacy
GLUT1 deficiency responds to ketogenic diet in myoclonic-astatic epilepsy (Mullen et al., 2011). Anti-epileptic synergies fail in advanced PME neurodegeneration. No disease-modifying therapies exist despite genetic targets (Florian et al., 2019).
Essential Papers
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
J. E. Wraith, Maurizio Scarpa, Michael Beck et al. · 2007 · European Journal of Pediatrics · 504 citations
Delineation of the motor disorder of Lesch–Nyhan disease
Hyder A. Jinnah, Jasper E. Visser, James C. Harris et al. · 2006 · Brain · 275 citations
Lesch-Nyhan disease (LND) is caused by deficiency of the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT). Affected individuals exhibit over-production of uric acid, alon...
Unstable TTTTA/TTTCA expansions in MARCH6 are associated with Familial Adult Myoclonic Epilepsy type 3
Rahel T. Florian, Florian Kraft, Elsa Leitão et al. · 2019 · Nature Communications · 161 citations
Basal ganglia calcifications (Fahr’s syndrome): related conditions and clinical features
Giulia Donzuso, Giovanni Mostile, Alessandra Nicoletti et al. · 2019 · Neurological Sciences · 157 citations
Basal ganglia calcifications could be incidental findings up to 20% of asymptomatic patients undergoing CT or MRI scan. The presence of neuropsychiatric symptoms associated with bilateral basal gan...
Classification of progressive myoclonus epilepsies and related disorders
Andermann, Andermann · 1990 · Annals of Neurology · 156 citations
Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients
Reijo Norio, Marjaleena Koskiniemi · 1979 · Clinical Genetics · 135 citations
In 107 Finnish patients with progressive myoclonus epilepsy (PME), belonging to 74 families, autosomal recessive inheritance was evident. The sex ratio was 48:51, the corrected proportion of affect...
Glucose Transporter 1 Deficiency as a Treatable Cause of Myoclonic Astatic Epilepsy
Saul A. Mullen, Carla Marini, Arvid Suls et al. · 2011 · Archives of Neurology · 134 citations
Objective To determine if a significant proportion of patients with myoclonic-astatic epilepsy (MAE) have glucose transporter 1 (GLUT1) deficiency. Design Genetic analysis. Setting Ambulatory and h...
Reading Guide
Foundational Papers
Start with Andermann and Andermann (1990; 156 citations) for PME classification framework, then Norio and Koskiniemi (1979; 135 citations) for genetic epidemiology in 107 patients.
Recent Advances
Study Florian et al. (2019; 161 citations) on MARCH6 TTTTA expansions in adult myoclonic epilepsy; Lehtinen et al. (2009; 125 citations) on cystatin B oxidative stress.
Core Methods
Sibship analysis for heritability (Norio and Koskiniemi, 1979); genetic screening for GLUT1 (Mullen et al., 2011); repeat expansion detection (Florian et al., 2019).
How PapersFlow Helps You Research Progressive Myoclonus Epilepsies
Discover & Search
Research Agent uses searchPapers and citationGraph on 'progressive myoclonus epilepsy' to map 156-cited Andermann and Andermann (1990) as hub, then findSimilarPapers reveals cystatin B links in Lehtinen et al. (2009). exaSearch uncovers obscure Finnish PME genetics from Norio and Koskiniemi (1979).
Analyze & Verify
Analysis Agent applies readPaperContent to extract oxidative stress data from Lehtinen et al. (2009), verifies inheritance claims in Norio and Koskiniemi (1979) via verifyResponse (CoVe), and runs PythonAnalysis on sibship proportions (0.260 affected) for statistical significance with GRADE B evidence grading.
Synthesize & Write
Synthesis Agent detects gaps in MARCH6 therapy post-Florian et al. (2019); Writing Agent uses latexEditText for PME classification tables, latexSyncCitations for 135-cited Norio paper, and latexCompile for review drafts, with exportMermaid diagramming genetic cascades.
Use Cases
"Analyze sibship data from Norio and Koskiniemi 1979 PME study for heritability stats"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas on 107-patient proportions, 0.260 sib risk) → matplotlib heritability plot output.
"Draft LaTeX review on PME classification with Andermann citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Andermann 1990) → latexCompile → PDF with nosology table.
"Find code for MARCH6 repeat expansion analysis from Florian 2019"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → TTTTA/TTTCA simulation scripts.
Automated Workflows
Deep Research workflow scans 50+ PME papers via citationGraph from Andermann (1990), chains to DeepScan for 7-step verification of cystatin B mechanisms (Lehtinen et al., 2009). Theorizer generates hypotheses on GLUT1-PME overlaps (Mullen et al., 2011) with CoVe checkpoints.
Frequently Asked Questions
What defines Progressive Myoclonus Epilepsies?
PME features triad of myoclonic jerks, seizures, ataxia progressing to neurodegeneration (Andermann and Andermann, 1990).
What are key PME genetic methods?
Autosomal recessive inheritance confirmed in 107 Finnish cases; cystatin B mutations cause EPM1 oxidative stress (Norio and Koskiniemi, 1979; Lehtinen et al., 2009).
What are foundational PME papers?
Andermann and Andermann (1990; 156 citations) classify disorders; Norio and Koskiniemi (1979; 135 citations) detail Finnish genetics.
What open problems exist in PME?
Disease-modifying therapies absent; variable expressivity hinders diagnosis despite MARCH6 expansions identified (Florian et al., 2019).
Research Glycogen Storage Diseases and Myoclonus with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Progressive Myoclonus Epilepsies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers